abt-100 has been researched along with Body-Weight* in 2 studies
2 other study(ies) available for abt-100 and Body-Weight
Article | Year |
---|---|
Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
Hutchinson-Gilford progeria syndrome (HGPS) is caused by the accumulation of a farnesylated form of prelamin A (progerin). Previously, we showed that blocking protein farnesylation with a farnesyltransferase inhibitor (FTI) ameliorates the disease phenotypes in mouse model of HGPS (Lmna(HG/+)). However, the interpretation of the FTI treatment studies is open to question in light of recent studies showing that mice expressing a nonfarnesylated version of progerin (Lmna(nHG/+)) develop progeria-like disease phenotypes. The fact that Lmna(nHG/+) mice manifest disease raised the possibility that the beneficial effects of an FTI in Lmna(HG/+) mice were not due to the effects of the drug on the farnesylation of progerin, but may have been due to unanticipated secondary effects of the drug on other farnesylated proteins. To address this issue, we compared the ability of an FTI to improve progeria-like disease phenotypes in both Lmna(HG/+) and Lmna(nHG/+) mice. In Lmna(HG/+) mice, the FTI reduced disease phenotypes in a highly significant manner, but the drug had no effect in Lmna(nHG/+) mice. The failure of the FTI to ameliorate disease in Lmna(nHG/+) mice supports the idea that the beneficial effects of an FTI in Lmna(HG/+) mice are due to the effect of drug on the farnesylation of progerin. Topics: Adipose Tissue; Animals; Body Weight; Disease Models, Animal; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fibroblasts; Imidazoles; Male; Mice; Phenotype; Prenylation; Progeria; Survival Analysis; Time Factors | 2010 |
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria.
Progerias are rare genetic diseases characterized by premature aging. Several progeroid disorders are caused by mutations that lead to the accumulation of a lipid-modified (farnesylated) form of prelamin A, a protein that contributes to the structural scaffolding for the cell nucleus. In progeria, the accumulation of farnesyl-prelamin A disrupts this scaffolding, leading to misshapen nuclei. Previous studies have shown that farnesyltransferase inhibitors (FTIs) reverse this cellular abnormality. We tested the efficacy of an FTI (ABT-100) in Zmpste24-deficient mice, a mouse model of progeria. The FTI-treated mice exhibited improved body weight, grip strength, bone integrity, and percent survival at 20 weeks of age. These results suggest that FTIs may have beneficial effects in humans with progeria. Topics: Animals; Body Weight; Disease Models, Animal; Enzyme Inhibitors; Farnesyltranstransferase; Female; Hand Strength; Imidazoles; Lamin Type A; Male; Membrane Proteins; Metalloendopeptidases; Mice; Nuclear Proteins; Progeria; Protein Precursors; Protein Prenylation; Rib Fractures; Survival Rate | 2006 |